Fig. 2From: Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIADConceptual figure denoting statistical approach to incorporate the variable treatment times of the enrolled study participants in the data analysisBack to article page